Seasonal Influenza – Epidemiology Forecast to 2028
- Pages: 45
- Published: October 2019
- Report Code: GDHCER219-19
Seasonal influenza is a contagious respiratory viral illness. There are four types of seasonal influenza viruses (A, B, C, and D); however, only types A and B cause human disease of public health concern (WHO, 2014). Influenza transmission occurs when people with flu cough, sneeze, or talk and disseminate droplets. These droplets can land in the mouths or noses of people who then inhale them into the lungs (CDC, 2018).
GlobalData epidemiologists used age- and sex-specific diagnosed prevalence rates to forecast the diagnosed prevalent cases. GlobalData epidemiologists applied country-specific prevalence rates of HS, wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.
The following data describes epidemiology of seasonal influenza cases. In 2018, the 8MM had 4,406,548 diagnosed incident cases of lab-confirmed seasonal influenza. This is expected to decrease to 4,285,297 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of negative 0.28%. In 2018, in the 8MM 380,179,080 people had received seasonal influenza vaccination. This is expected to increase to 409,507,606 people receiving seasonal influenza vaccination by 2028 at an AGR of 0.77%. The variations in diagnosed incident cases of lab-confirmed influenza, and vaccination rates may be due to differences in the healthcare systems and government vaccination programs in each market. Although GlobalData epidemiologists do not expect any significant changes that would increase the vaccination rates for seasonal influenza in the 8MM, changes in vaccination guidelines and efforts to increase awareness and perception of influenza vaccination may occur and lead to an increase in vaccination uptake.
The Seasonal Influenza Epidemiology Report and Model provide an overview of the risk factors and global trends of seasonal influenza in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Brazil).
This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 8MM: the diagnosed incident cases of lab-confirmed seasonal influenza, lab-confirmed seasonal influenza mortality, and vaccination rates for seasonal influenza.
The seasonal influenza epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to buy
The Seasonal Influenza Epidemiology series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global HS market.
Quantify patient populations in the global seasonal influenza market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for seasonal influenza vaccines in each of the markets covered.
Understand magnitude of lab-confirmed seasonal influenza mortality.
Quantify the population receiving seasonal influenza vaccination.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Seasonal Influenza: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Seasonal Influenza (2018–2028)
3.5.1 Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza
3.5.2 Age-Specific Diagnosed Incident Cases of Disease of Lab-Confirmed Seasonal Influenza
3.5.3 Sex-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza
3.5.4 Lab-Confirmed Seasonal Influenza Mortality
3.5.5 Age-Specific Vaccination of Seasonal Influenza
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4.2 About the Authors
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
List of Tables
Table 1: Risk Factors and Comorbidities for Seasonal Influenza
List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, Both Sexes, All Ages, 2018 and 2028, N
Figure 2: Diagnosed Incidence of Lab-Confirmed Seasonal Influenza, Men, Women, All Ages, Cases per 100,000 Population, 2018
Figure 3: 8MM, Sources Used and Not Used for Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza
Figure 4: 8MM, Sources Used for Lab-Confirmed Seasonal Influenza Mortality
Figure 5: 8MM, Sources Used for Proportion of People Receiving Seasonal Influenza Vaccination
Figure 6: Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, 8MM, Both Sexes, All Ages, 2018
Figure 7: Age-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, 8MM, Both Sexes, All Ages, 2018, N
Figure 8: Sex-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, 8MM, All Ages, 2018, N
Figure 9: Lab-Confirmed Seasonal Influenza Mortality, 8MM, Both Sexes, All Ages, 2018, N
Figure 10: Age-Specific Cases of People Receiving Seasonal Influenza Vaccination, 8MM, Both Sexes, All Ages, 2018, N